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Summary The 50% survival time for low grade astrocytomas is 50 months and for high grade astrocytomas
it is 13 months, underlining the need for new therapies. Several reports show that in vivo histamine antagonists
cause retardation of tumour growth in some animal models and prolonged survival in cancer patients.
Therefore we have tested the growth modulating effects of histamine and histamine antagonists on human
glioma cultures.
Twelve freshly excised human gliomas were cultured and tested for their in vitro sensitivity to histamine and
histamine antagonists. Four continuous glioma cell lines were used to confirm the glioma-specificity of the
effects observed in the primary cell lines. In low serum concentration (0 or 1%) the growth of 5/9 primary
glioma-derived cultures could be stimulated with 0.2 mm histamine, and in 4/5 cases with 0.2 tLM histamine.
One mm of the histamine H2-receptor antagonist cimetidine could inhibit the growth of 4/5 primary glioma
cultures when tested in 1% human AB serum, and of 6/13 cases when tested in 1% FCS. Lower concentra-
tions (down to I fLM) were less effective. The histamine HI-receptor antagonist pyrilamine gave variable results.
The specificity of the effects is indicated by the absence of a generalised toxic effect, by the observation that
the antagonist-induced inhibition could be reversed with histamine, and by the correlation of the obtained
cimetidine-induced growth inhibition with the maximal growth rate of the primary cell lines in 10% FCS.
The observed cimetidine-induced inhibition of the in vitro proliferation of gliomas suggests that cimetidine is
a relevant candidate for the in vivo growth inhibition of these tumours.
The prognosis for patients with glioma is poor. Around 1950
the time for survival to fall to 50% was 46 months for low
grade and 9 months for high grade astrocytomas (Svien et
al., 1949). These discomforting figures have shown only a
very limited improvement (Nazarro & Neuwelt, 1990); 40
years later 50% survival is 50 and 13 months for low grade
and high grade astrocytomas respectively (Daumas-Duport et
al., 1988), which is mostly due to changes in surgical tech-
nique and anaesthetics. While radiotherapy has some minor
effect on the duration of survival, cures have not been
reported (Leibel & Sheline, 1987). Chemotherapy is as yet
ineffective in the treatment of astrocytoma (Kornblith &
Walker, 1988). Although prognosis in oligodendrogliomas is
slightly better (Smith et al., 1983), chemotherapy and irradia-
tion likewise have no, or a very limited effect (Leibel &
Sheline, 1987; Kornblith & Walker, 1988). New approaches
in glioma therapy are therefore needed. We have examined
the proliferation modifying effects of histamine, the Hl-
receptor antagonist pyrilamine and the H2-receptor
antagonist cimetidine on glioma cell lines in order to select a
possible candidate for in vivo tumour growth suppression.
Histamine can act, at least in part, as a growth factor, as the
rate of tissues proliferation in wound repair, embryogenesis,
and malignant growth is related to the level of histamine
production (Kahlson & Rosengren, 1968). Locally syn-
thesised histamine favours tumour cell growth both by autoc-
rine stimulation and by activating T-suppressor cell function
(Bartholeyns & Fozard, 1985).
Histamine can exert its action through binding at Hr- or
H2-receptors. Specific agonists and antagonists for both
receptors are useful tools in research concerning the growth
stimulating action of histamine. Thus, it has been reported
that tumour growth can be stimulated by histamine alone or
combined with the HI antagonist mepyramide, or by the
histamine H2 agonist dimiprit in experimental in vivo models
(Tutton & Barkla, 1978; Burtin et al., 1982). Histamine H2
antagonists (cimetidine or metiamide) inhibit tumour cell
growth (Tutton & Barkla, 1978; Tutton & Steel, 1979; Burtin
et al., 1982; Tutton & Barkla, 1987). Apparently, histamine
favours in vivo tumour cell proliferation via the H2-receptors.
Cimetidine therapy given for epigastric distress in two
patients with lung carcinoma caused tumour regression in the
absence of any antitumour therapy (Armitage & Sidner,
1979). In addition, cimetidine therapy for epigastric com-
plaints in patients with gastric cancer induced a prolonged
survival (Scotcher et al., 1981). Patients with advanced
cancers predominantly of the digestive tract survived longer
after treatment with cimetidine alone (Tonnesen et al., 1988)
or cimetidine combined with histamine (Burtin et al., 1988).
These findings offer a rationale for our study of the growth
modulating effects of histamine and histamine antagonists on
glioma cell lines.
Materials and methods
Tumours, cell lines, and culture system
Twelve cerebral glial tumours were obtained at surgery. The
tumours were put into tissue culture as soon as possible,
usually within 2 h after surgical removal. To obtain a cell
suspension, the tumours were minced and digested with an
enzyme solution containing collagenase type I (0.05% w/v;
Worthington), dispase grade II (1.25 U ml-', Boehringer
Mannheim) and hyaluronidase (0.1% w/v; Boehringer) dis-
solved in Dulbecco's Modified Eagles Medium (DMEM)
supplemented with 10% heat inactivated Fetal Calf Serum
(FCS; Gibco, Paisley) (Pleasure et al., 1986). After 2 h of
digestion at 37°C with continuous gentle agitation, the result-
ant cell suspension was washed and cultured in 25 cm2 plastic
culture flasks (Costar, Cambridge, MA, USA) at 37°C in 5%
CO2 in air. Solid tumours required an overnight incubation
in an 1:20 diluted enzyme solution (diluted in DMEM with
10% FCS). The emerging cell lines were marked with a lab
identifier (PU, Table I), which is omitted in the text, and a
individual code.
Four continuous glioma cell lines were used in order to
confirm the glioma-specificity of the effects observed in the
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primary cell lines. U87MG, U138MG and U373MG (Ponten
& Macintyre, 1968) were purchased from the ATCC; the
U343MG line was a gift from C.-H. Heldin (Nister et al.,
1986). Cells were cultured in DMEM supplemented with
penicillin (102 U ml'; Northumbria Biologicals, Cramling-
ton), streptomycin (102,jg ml-'; Northhumbria), neomycin
(0.1 mg ml-'; Gibco, Chagrin Falls, OH, USA). In the
regular culture system 10% heat inactivated FCS was added.
To passage the cultures, the adhering cells were dissociated
by incubating them for 2 min with 0.1% trypsin (Sigma
Chemicals, St. Louis, MO USA) dissolved in a Ca2", Mg2+
free medium, and split in a 1:4 ratio.
Characterisation ofprimary cultures
For the characterisation of primary cultures we relied on the
morphological criteria for identification of cultures derived
from gliomas as described by Ponten (Ponten & Macintyre,
1968) and Freshney (1980). If a sufficient number of cells was
available, the glioma tumour cultures were characterised with
immuno-staining for glial fibrillary acidic protein (GFAP).
For this purpose, cells were cultured in 8-chamber Lab-teks
(Nunc, Naperville, IL USA), fixed in acetone, and incubated
with antibodies to GFAP (Eurodiagnostics Apeldoorn, The
Netherlands). Bound antibody was visualised using a
biotinylated second antibody (goat anti-rabbit from Vector
Laboratories, Burlingame, CA USA) and the avidin-biotin-
horseradish peroxidase complex method (ABC, Vector) (Hsu
et al., 1989). As a chromogenic substrate 3',3'-diamino-
benzidine (Sigma) was used.
The DNA index was determined from the cell cultures. For
this purpose, 106 cells were harvested, washed, and incubated
with 90 U ml-' RNAse A (Worthington) in an agitating
waterbath at 37°C for 30 min. Then cells were stained with
ethidium bromide (Sigma), and analysed in an FACS
analyser (Becton Dickinson) (Rutgers, 1981). As control cells
we used normal human peripheral blood lymphocytes.
For karyotyping, demicolchine was added to cell cultures
in log phase to a final concentration of 0.02lg ml-' for
30 min at 37°C. The cultures were trypsinised to obtain a
single cell suspension and metaphase preparations were made
after standard hypotonic (0.075 M KCI) and fixation (3:1
methanol:glacial acetic acid) procedures. Cytogenetic
analyses were carried out after staining with Atebrine to
obtain Q-banding and the findings described according to the
standard nomenclature (ISCN, 1991).
Experimental system
For stimulation experiments 2,500-4,000 cells per well were
seeded in 96-wells plates (Costar). The experiments were
carried out in 4-6 duplicates. Serum, histamine (0.2 IM-
0.2 mM; Sigma), pyrilamine (100,M; Sigma) and cimetidine
(1 fM-1 mM; Sigma) were added at day 0. Histamine and
histamine antagonist concentrations were derived from
literature (Jordana et al., 1988; Tilly et al., 1990). In the
experiments we used 1% FCS (with some exceptions, as
indicated in the results) to obtain low level proliferation.
Under these conditions both stimulation and inhibition of
proliferation could be measured relative to control prolifera-
tion (1% FCS alone). Some experiments were repeated with
1% pooled human AB serum. The influence of low histamine
concentration on glioma cell proliferation was also tested
without serum. In all low serum experiments the culture
medium was enriched with transferrin (10 tgml-'; Sigma),
sodium pyruvate (1 mM; Sigma), sodium selenite (30 pM;
Sigma), 3,3',5-triiodo-L-thyronine (7.5 nM; Sigma), MEM
Non Essential Amino Acids (1:100, Sigma), and BME
vitamins (mixture; 1:100, Sigma).
Growth curves were constructed by recording cell density
as a measure of cell proliferation at 2-3 day intervals within
10-12 days after seeding (e.g. at days 1, 3, 6, 8 and 10). For
this purpose we used a protocol adapted from Pelletier
(Pelletier et al., 1988). Briefly, glutaraldehyde (25%) was
added to the wells and washed away after 20 min with warm
tapwater (30°C); then methylene blue (0.05%) was added for
15 min and washed away with tapwater at 30°C; the bound
dye was extracted from the cells with 0.33 M HCI and the
absorbance of the dye in the wells was recorded in a Titertek
multiscan spectrophotometer at 620 nm. This method gave
reliable data in growth rate studies using adhering cells
(Pelletier et al., 1988). In our system, this method gave a
linear correlation for the number of seeded cells and the
extinction for 1,500-65,000 cells per well (corresponding
extinction values 0.020-1.100). The number of population
doublings (PD) from the first to the last measure point (day a
- day n) was calculated from extinction values measured on
these days (Ea and En) using the formula: PDday(a n) = 2log(En/
Ea). Results of the growth experiments are presented as the
calculated difference between the mean number of population
doublings in 4-6 control and test wells. Significance for this
difference was calculated with the Student's t test; the result-
ing P-values are presented as: *P<0.05, **P<0.005 and
***P<0.0005.
Results
Cell cultures
Twelve tumours were cultured successfully (Table I, first
column). In one case (G233) two different parallel cultures
were derived from the original tumour suspension. Tumour
suspensions could be subcultured for at least eight passages.
Studies were carried out on early passages to reduce the
possibility of overgrowth of fibroblasts, normal glial and
endothelial cells, and to prevent further transformation. This
implies that a complete set of experiments could only be
executed if more than one gram of tissue was available.
Usually we received smaller amounts (0.2-0.5 gram); for this
reason not all experiments were performed on each individual
primary cell line.
Characterisation ofcell lines
The second column of Table I shows the original histo-
pathological diagnosis of the cultured tumours, named in
the first column, classified according to Kernohan et al.
(1949). The doubling time of the primary cell lines was
18-73 h under optimal conditions (10% FCS; column 4).
This growth rate is given for early passages (<P5). Three
out of 12 primary cell lines seemed to be immortalised, as
they could be passaged more than 20 times. The fact that
4/12 of our cultures died after a relatively low number of
passages is in line with the observation that approximately
50% of human glioma cultures do not establish (Bigner &
Mark, 1984).
The primary cultures, observed by phase-contrast micros-
copy, showed disoriented growth and loss of contact inhibi-
tion. The morphology of the individual cells varied between
cultures and included irregularity within and between the
different cases, haphazard orientation and postconfluential
growth. All cells showed a clearly visible cell-body with a rim
of cytoplasm around the nucleus, and in most cultures cells
had a multipolar appearance, caused by multiple irregular
cytoplasmic processes. In our series we found a variation in
the aspect of these processes from relatively compact to very
long and slender (Figure la and b). Figure lb also shows
broadening and flattening of some processes, suggesting a
polarity that may reflect migratory activity of the cell
(Forsby et al., 1986). Figure lc shows the poorly
differentiated, fibroblast-like aspect of cell line G47.
When stained for the expression of GFAP (Table I, 6th
column), all tested cell lines showed positive staining. Stain-
ing intensities varied from intense (3/8 cases) to moderate
(4/8) and weak (1/8).
DNA measurements were carried out on six cell lines, using
fluorescent flow cytometry. Table I, 7th column shows the
DNA index of these cell lines, which indicates that hyper-478 L.T.M. VAN DER VEN et al.
a G47 had a wide range of numerical and structural changes. A
total of 15 metaphases was karyotyped and the chromosome
number varied between 74-79 and 126-155. There was no
definite modal number. Clonal structural changes involved
chromosomes 1, 5, 6, 7, 9, 11, 17 and 19. A representative
karyotype is shown in Figure 2. Two copies of the struc-
turally abnormal chromosomes were present in the cells with
126-155 chromosomes, demonstrating that polyploidisation
had occurred during tumour progression. Cell lines G223 and
G233 were in the diploid range. G223 had a complex hypo-
ploid mainline karyotype with structural variation involving
chromosomes 1, 2, 3, 4, 5, 6, 7, 9 and 14. The Y chromosome
and a chromosome 13 were missing. Cytogenetic studies were
carried out twice on the cell line G233. In culture G233/a,
analysis of eight metaphases revealed two cells with a trans-
location t(6;8)(pl2;p22). Analysis of a parallel culture (G233/
b) demonstrated the presence of an abnormal cell line with
the mainline karyotype 48,XX,+3, +7,add(13)(pl1). Cell line
G226 had an apparently normal karyotype.
b
Figure 1 Photomicrographs of primary glioma cell lines: a com-
pact multipolar cell type with irregular processes of intermediate
length, haphazard cell orientation (G226, passage 6); b multiple
long and slender processes in G177 (passage 5); arrows indicate
flattening of these processes, suggesting migratory activity; c
poorly differentiated, fibroblast-like cells in G47 (passage 19).
Phase-contrast, scale bar represents 50 i.
ploidy was found in 3/3 grade IV and 1/2 grade III
astrocytoma-derived cultures; a diploid peak was found in
1/2 grade III and 1/1 grade II astrocytoma-derived culture.
Chromosome analysis was successfully carried out on four
cell lines, G47, G223, G226 and G233 (Table I, last column).
Effects ofhistamine and histamine antagonists onproliferation
Cells were cultured at suboptimal conditions in order to be
able to measure positive and negative effects of the added
factors on proliferation. In most cultures this was realised
using 1% serum. However, cell line U138MG and U373MG
were tested at 0.5% and 0.25% serum, respectively, because
of high proliferation rate at 1% serum. Figure 3a shows an
example of the growth curves in one such an experiment. The
cell line G15 showed maximal proliferation with 10% FCS,
giving a population doubling time of 44 h in the middle log
phase, which is transported to Table I. The effects of his-
tamine, cimetidine and pyrilamine were measured during
logarithmic growth (day 3-10) in 1% FCS. The differences
in number of population doublings between the growth
curves and the control growth curve (1% FCS) were cal-
culated and transported to Figure 3b and Table II.
In this table, the results of the stimulation/inhibition
experiments are summarised. Cell lines G233/a and G233/b
are considered as separate cultures. The addition of 0.2 mM
histamine induced significant stimulation of proliferation in
primary cell lines both tested with 1% FCS (3/9 cases) or 1%
AB serum (2/3 cases), and also in continuous cell lines (2/4
cases tested with FCS and in 1/4 tested with AB serum).
Inhibition of proliferation was found in one case (U87MG).
Addition of 0.2 tIM histamine induced significant stimulation
of proliferation in 0/2 continuous cell lines and in 2/2
primary cell lines, but only when tested with AB serum.
Without serum addition, 0.2 jSM histamine induced significant
stimulation in 2/3 primary and in 1/1 continuous cell lines. In
summary, proliferation of 2/4 continuous cell lines and of
9/13 primary cell lines was stimulated with histamine in one
or the other tested condition, inhibition occurred in 1/4
continuous cell lines.
The addition of 1 mM cimetidine induced significant inhibi-
tion of proliferation in 2/4 continous cell lines when tested
with FCS and in 3/4 cases lines when tested with AB serum.
The proliferation of the primary cell lines was inhibited
significantly with 1 mM cimetidine in 4/13 cases when tested
with FCS and in 4/5 cases when tested with AB serum,
making a total of 6/13 primary cell lines that were reactive to
cimetidine.
The effect of the addition of 0.1 mM pyrilamine was
variable. The combined results of FCS and AB serum show
that inhibition was found in 3/4 continuous cell lines and in
2/8 primary cell lines, while 3/8 primary cell lines were
stimulated.
Because of the consistent inhibiting effect of cimetidine, we
tested the effect of lower concentrations in two responsive
continuous cell lines and two responsive primary cell lines.
Figure 4 shows that maximal inhibition is obtained at 1 mM
cimetidine in all four cases and that there was a dose-
response relation in two cell lines (U138MG and G226). G15
showed significant inhibition even at 1 tLM cimetidine.GLIOMA SENSITIVITY FOR HISTAMINE 479
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Figure 3 a, Growth curves of G15, illustrating the maximal
observed growth rate at 10% FCS ( ) and the effect of
histamine and histamine antagonists at I% FCS. 1% FCS,
- - - 0.2 mM histamine, - 1 mM cimetidine, --- 0.1 mM
pyrilamine. b Changes in number of population doublings from
day 3-10 due to histamine and histamine antagonists in the
presence of I % FCS, calculated from the growth curves in Figure
3a. M histamine, _ cimetidine, M pyrilamine. *P<0.05,
**P <0.005.
Figure 4 Response of four glioma cell lines to different
cimetidine doses, expressed as the difference between the number
of population doublings of the control growth curve (1% FCS
alone) and the test growth curve (1% FCS + cimetidine). The
used concentrations were: _ 1 mm, 0.1 mM, m 1O tIM,
and f 1 tiM cimetidine. *P<0.05, **P<0.005 and
***P<0.0005.
Specificity ofthe measured inhibition
In order to test the specificity of the observed inhibition with
cimetidine and pyrilamine, the effect of addition of 0.2 mm
histamine to the cimetidine-inhibited culture was tested in
one continuous cell line (U138MG) and in two primary cell
lines (GI5 and G611). The same test was performed in the
pyrilamine-inhibited culture of one continuous cell line
(U138MG) and one primary cell line (G47). Figure 5a shows
that histamine addition significantly reversed the cimetidine-
induced effect in U138MG and in G611. Figure Sb shows
that pyrilamine-induced inhibition was significantly reduced
in both cases.
Correlation ofcimetidine-induced growth inhibition with the
maximal growth rate
The observations with the primary cell lines suggested an
inverse correlation between cimetidine responsiveness and the
maximal growth rate of a given cell line, observed with 10%
FCS addition. This was confirmed by calculating the linear
regression between these two parameters (Figure 6). The
correlation coefficient was - 0.73 with a chance probability
Table II Effects of histamine, cimetidine and pyrilamine on proliferation of glioma cell cultures
FCSa ABb Oc FCS AB FCS AB
his Hd hisLe hisH hisL hisL cimf cim pyr4 pyr
Continuous cell lines
U87MG bh 4 = 4 =
U138MG t = 44+4 44+ +44 44+
U343MGa = = - 4'4 , =
U373MG tt = = = +4'4 4'4 444 4'44
Primary cell lines
PU-G15 = 44'4 4'i+44 4'4''
PU-G24 = t 4'4' 4'4+44 = tll
PU-G47 t +44';
PU-G162 = = = 4'4'4=
PU-G177 t = t
PU-G189 =
PU-G223 =
PU-G226 + 4'4'
PU-G233/a = 4 =
PU-G233/b = =
PU-G283
PU-G311 = t- = ++4
PU-G611 = - =
aFCS: tested with foetal calf serum; bAB: tested with pooled human AB serum; CO: tested without serum addition; dhisH:
0.2 mm histamine; ehisL: 0.2j5M histamine; fcim: 1 mM cimetidine; gpyr: 0.1 mM pyrilamine; hstimulation or inhibition of cell
proliferation: t/4' <0.5 population doublings, tt/4'4' 0.5- 1 population doublings, t44t/4'4'4' > 1 population doublings,
= no stimulation or inhibition (scores represent the mean of 4-6 duplicates and were significant in the Student's 't' test).
Serum was added in a concentration of 1%, except in U138MG and U373MG, which were tested at 0.5% and 0.25%
serum, respectively.
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Figure 5 Effect of the addition of histamine on cimetidine-
induced growth inhibition (a) and on pyrilamine-induced growth
inhibition (b). The bars represent the difference between the
number of population doublins of the control growth cruve (1%
FCS alone) and the curve of the test. The used concentrations
were: M mM cimetidine in a, 0.1 mm pyrilamine in b,
the antagonist+0.2mm histamine. *P<0.05, **P<0.005 and
***P<0.0005.
of 0.011. No significant correlation was found for histamine-
induced stimulation or pyrilamine-induced effects.
Discussion
Characterisation
Positive staining for GFAP, found in 7/8 of our primary
cultures, is indicative for a glial phenotype. Low staining
intensity in 1/8 of our cultures agrees with the finding of low
GFAP contents reported for 1/5 continuous glioma cell lines
(Ito et al., 1989).
Cytogenic studies on cell lines G47 and G223 revealed
complex karyotypes with structural and numerical variation.
Both of these lines were derived from high grade tumours.
The association between complex karyotypic changes and
high malignancy in brain tumours has been reported recently
by Kimmel et al. (1992). Of particular note is the presence of
structural abnormalities involving the short arm of
chromosome 9 in cell lines G47 and G223. Kimmel et al.
(1992) also demonstrated that aberrations of 9p appear to be
continued to brain tumours of high malignancy. Molecular
studies using a range of probes for this region of
chromosome 9 have shown that loss of DNA sequences
occurs at a significant frequency in gliomas and may repre-
0.6
n \\
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15 75
Doubling time (h)
Figure 6 Regression curve representing the correlation between
cimetidine-induced inhibition observed at 1% FCS and the max-
imal measured growth rate of primary glioma cell lines at 10%
FCS; the cimetidine-induced inhibition is expressed as the
difference between the number of population doublings between
the control growth curve (serum alone) and the test curve
(cimetidine added).
sent an important step in the progression of these tumours
(Olufunmilayo et al., 1992). Loss of heterozygosity for
genetic loci on the long arm of chromosome 10 also occurs
frequently in gliomas (Rasheed et al., 1992); cell line G47 had
a deletion of region 10ql2q24. The other chromosomal
abnormalities found in these two cell lines are typical of these
reported for glioma (Jenkins et al., 1989; Ransom et al.,
1992). Cytogenic studies were carried out twice on cell line
G233. Line G233/a had been maintained serially in tissue
culture from the original tumour biopsy. Line G233/b was
derived from cells cultured after storage in liquid nitrogen at
a very early stage of growth of the original tumour. In both
lines G233/a and G233/b abnormal clones were identified,
but with different chromosomal abnormalities within the
diploid range. This suggests either that the observed
karyotype changes are a culturing artefact or that they repre-
sent a selection of the original tumour cell population. Line
G233/b had trisomy 7 which had been reported as a cultur-
ing artefact in normal brain cells (Heim et al., 1989), but is
also one of the more common changes found in gliomas
(Bigner et al., 1988; Arnoldus et al., 1991). The normal
karyotypes of culture G226 and the main population of
culture G233/a may indicate that these cultures originated
from gliomas with a comparatively homogeneous population
of near-diploid cells, which form the majority of gliomas
(Bigner & Mark, 1984).
The finding with flow cytometry of an aneuploid peak in
all four tested high-grade gliomas and diploid peak in one
high-grade and one low-grade glioma agrees with the dist-
ribution found by others (Onda et al., 1988; Spaar & Spaar,
1990).
Morphology and GFAP staining indicate that the used
method was successul in establishing primary glioma cell
cultures. As mentioned above, karyotyping and flow
cytometry suggest a distribution and specificity of anomalies
corresponding with those found for gliomas. Another argu-
ment for the glioma nature of our cultures is that the results
of the continuous cell lines parallel those of the primary cell
lines. On the other hand, it should be considered that it is
most likely that even the early passage populations represent
a selection of the original tumour heterogeneity (Shapiro et
al., 1981). In addition the findings with cytogenetic and flow
cytometric studies in the near-diploid range may be of non-
tumorous origin, and aneuploid findings may be generated in
vitro, as we did not make direct preparations in order to
identify original tumour characteristics (Shapiro et al., 1981;
Onda et al., 1988).
Sensitivity to histamine and histamine antagonists
We could detect significant histamine-induced stimulation of
proliferation in 12/16 tested glioma cell lines. This effect was
found both in the continuous and in the primary cell lines.
The differences that were found under the various test condi-
tions (FCS, AB-serum, no serum) reflect differences in pro-
liferation modulating capacity of the sera used. A growth
stimulating effect of histamine has been implicated in other in
vitro systems. Stimulatory activity via HI-receptors was found
to occur in HeLa and A431 human carcinoma cells and A875
human melanoma cells (Tilly et al., 1990); and in normal
human lung fibroblasts (Jordana et al., 1988), normal canine
airway smooth muscle cells (Panetteiri et al., 1990), normal
rat astrocytes (Rodriguez et al., 1989) and normal murine
haematopoietic stem cells via the H2-receptors (Schneider et
al., 1990).
Cimetidine significantly inhibits cell proliferation in the
majority of cell lines in the present study. This indicates the
dependence of proliferation of these cell lines on stimulation
of the H2-receptor. In three cell lines that showed no res-
ponse to cimetidine in the presence of FCS, a significant
inhibition was found in the presence of AB serum. This
confirms the relative importance of histamine stimulation for
cells cultured with AB serum.
At low serum concentrations pyrilamine induced significant
inhibition in 5/11 tested cell lines and stimulation in 2/11 cell482 L.T.M. VAN DER VEN et al.
lines. Inhibition of cell proliferation was also found in HN-1
human squamous carcinomas cells (Bijman et al., 1987) and
normal human skin fibroblasts via HI-receptors (Johnson &
Johnson, 1990).
Three observations indicated that histamine antagonists
induced a specific inhibition of proliferation and no non-
specific cytotoxic effect. First, there was a cell line specific
sensitivity to the addition ofcimetidine or pyrilamine as these
factors could not inhibit proliferation in all cell lines. Second,
the cimetidine-induced inhibition of proliferation obtained at
low FCS concentration was inversely correlated with the
maximal growth rate observed at 10% FCS (Figure 6), sug-
gesting a decreasing importance of stimulation of the H2-
receptor with increasing growth rate. Fast growing cell lines
may have accumulated more mutations that make them sen-
sitive to multiple growth stimuli (Den Otter et al., 1990) and
thereby less depending on each separate stimulus, in casu
histamine. Third, the observed histamine antagonist-induced
inhibitions were reversed in some cell lines. The effects of
histamine and its antagonists were not related to histology or
classification of the original tumour.
Importance ofhistamine and histamine antagonists
In five cell lines, addition of histamine in a concentration
approaching the whole blood level (0.2l4M) could stimulate
proliferation. In two cell lines (U138MG and U373MG),
addition of 0.2 mM histamine was more effective than 0.2 JM.
In this respect it is noteworthy that within a tumour the
histamine level can rise due to local production (Ahlstrom et
al., 1966; Bartholeyns & Fozard, 1985; Johnston, 1967; Kahl-
son et al., 1963; Mackay et al., 1960). This implicates that
even in vivo cells with low sensitivity to histamine may be
stimulated to proliferate by this factor. Another implication
of the histamine-forming capacity of tumour cells is that
autocrine stimulation of glioma cell proliferation may be
involved. Therefore, the histamine antagonist-induced inhibi-
tion of proliferation may reflect interference with stimulation
by nascent histamine rather than with stimulation by serum-
derived histamine.
Our experiments indicate that both H2- and HI-receptors
can be involved in the proliferation of glioma cells. Both
receptors can be active on the same cell, as is illustrated by
the histamine-induced vasodilatation, where both Hl- and
H2-receptors are active in the relaxation of smooth muscle
cells of small vessels (Douglas, 1985). An alternative explana-
tion is that in the glial tumours and the cultures that were
derived from these tumours, two different cell populations
were present, one bearing HI-receptors and the other bearing
H2-receptors. In a cultured glial tumour several subpopulations
can be present (Westermark et al., 1985; Shapiro et al., 1981).
Cimetidine-induced inhibition was most prominent at a
high concentration, that would be toxic in vivo. However, in
the physiological situation, cell proliferation is regulated by
the concerted action of balanced concentrations of various
growth factors with stimulating and inhibiting actions (Sporn
& Roberts, 1985; 1988). The in vitro system lacks this delicate
balance of stimuli. Therefore the impact of a lower concent-
ration of a histamine receptor-blocking agent may be more
prominent in vivo. This is supported by the obtained in vivo
tumour growth-inhibiting effect of non-toxic concentrations
of H2-receptor antagonists as mentioned in the Introduction.
A particular problem concerning in vivo application of a
water-soluble drug like cimetidine in the brain is the blood-
brain barrier. However, this barrier has been reported to be
non-functional in nearly all tumours (Wolff & Boker, 1989),
or at least to a high extent in different gliomas or in different
regions of a tumour (Shapiro & Shapiro, 1986). This is due
to ultrastructural changes like interendothelial junction
abnormalities and fenestrations in tumour vessel walls,
leading to increased permeability (Stewart et al., 1985).
As noticed, subculturing human gliomas induces selection.
Nevertheless, the high proportion of cultures that was reac-
tive to histamine and its antagonists suggests a widespread
sensitivity.
Conclusions
We conclude that histamine can be a potent growth
stimulating factor for cell cultures that originate from human
glial tumours. The H2-receptor was involved more con-
sistently in this growth stimulation than the HI-receptor, and
blocking the H2-receptor induced growth inhibition in high
proportion of the cultures. In vivo, histamine H2-receptor
antagonists can prolong survival in hosts bearing various
human and animal tumours. Therefore, H2-receptor
antagonists are potential candidates for the postsurgical
treatment of glioma patients, depending on the extent of
breakdown of the blood-brain barrier in the tumour.
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